RT Article
T1 Prevalence of legal, prescription, and illegal drugs aiming at cognitive enhancement across sociodemographic groups in Germany
JF Deviant behavior
VO 46
IS 3
SP 253
OP 287
A1 Sattler, Sebastian
A1 van Veen, Floris
A1 Hasselhorn, Fabian
A1 El Tabei, Lobna
A1 Fuhr, Uwe 1960-
A1 Mehlkop, Guido 1972-
A2 van Veen, Floris
A2 Hasselhorn, Fabian
A2 El Tabei, Lobna
A2 Fuhr, Uwe 1960-
A2 Mehlkop, Guido 1972-
LA English
YR 2025
UL https://krimdok.uni-tuebingen.de/Record/1918954941
AB There has been speculation about a growing demand for substances used without medical need for cognitive enhancement (CE). Thus, the prevalence rates and the identification of sociodemographic groups at risk of this behavior need further description and constant monitoring. We conducted a nationwide web-based representative sample (N = 22,101) (regarding sex, age, education, and federal state) of the general adult population in Germany. Results show a high past twelve months prevalence of consuming caffeinated drinks for CE (62.4% of respondents), followed by food supplements and home remedies (31.4%), and caffeine tablets (2.5%). The twelve-month prevalence of CE with prescription drugs was 3.7% (lifetime: 5.5%), of whom 29.1% reported using them 40 or more times; 40.5% of all respondents indicated some future intake willingness. Cannabis was the most frequently reported illegal drug for CE (past twelve months: 4.0%; lifetime: 10.7%), followed by the category amphetamine and methamphetamine (past twelve months: 1.0%; lifetime: 2.4%), and cocaine (past twelve months: 0.9; lifetime: 2.4%). We also show variation in the prevalence across multiple ascribed and achieved sociodemographic characteristics. These results can inform public policy and prevention strategies regarding the continued monitoring of the prevalence of CE and the identification of groups at risk of drug misuse.
NO Literaturverzeichnis: Seite 280-287
NO Correction zum Artikel: https://doi.org/10.1080/01639625.2024.2438547
K1 Droge
K1 Prävention
K1 Kriminologie
K1 Empirische Forschung
DO 10.1080/01639625.2024.2334274